Chinese pharma giant has appointed Dr Hausheer as Chief Medical Officer
Dr Frederick H. Hausheer
Dr Frederick H. Hausheer, a global oncology clinical drug development expert, has taken on the role of Chief Medical Officer at WuXi AppTec, the Chinese pharmaceutical and medical device company.
In his new role, Hausheer will be responsible of leading WuXi's clinical operations in the US, China and other territories.
In addition, he will play a key role in forging and maintaining strong connections between customers and WuXi’s business units by providing inputs on medical and clinical development strategies aimed at seamless integration from preclinical translational research and development into first-in-human studies, as well as for Phase I-IV clinical development plans for our customers.
“We’re very excited to welcome Dr Hausheer onboard as our Chief Medical Officer,” said Edward Hu, Co-CEO of WuXi AppTec. “Dr Hausheer’s rich experience in global oncology clinical drug development and translational science and medicine makes him ideally suited to taking this role. We are confident in his leadership to strengthen WuXi’s clinical development capabilities and capacity globally, and enable more customers to develop better medicine faster to benefit patients around the world.”
Dr Hausheer brings more than 30 years' experience in global oncology clinical drug development and translational science and medicine in commercial and academic settings.
He has extensive experience in translational/IND programs, clinical trial design, commercial clinical development, and involvement in regulatory interactions for novel agents spanning from pre-IND and Phase I-III development in the United States, China, Europe, Japan and other territories.
Prior to joining WuXi, Dr Hausheer held CEO and CMO positions with several Biopharma companies and was the founder and Chairman of BioNumerik Pharmaceuticals.
Dr Hausheer has also served as a business advisory board member to JP Morgan Chase, the Whittaker Institute at Johns Hopkins, and the National Cancer Institute.
Early in his career, he served on the National Cancer Institute (NCI) Experimental Therapeutics Section, the NCI Decision Network Panel, and the NCI Institutional Review Board, followed by extensive involvement in national and international Phase I-III clinical trials involving novel treatments for lung, breast, ovarian and other malignancies.
Dr Hausheer obtained his MD at the University of Missouri, School of Medicine and then became a faculty member at the Johns Hopkins Oncology Center, where he focused on the development of novel experimental therapeutics and pharmacology.